LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the ...
T2 Biosystems (TTOO) has announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its COVID-19 molecular diagnostic test, the T2SARS-CoV-2 Panel.
LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced ...
Shares of T2 Biosystems Inc. extended their losing streak to two days Wednesday despite the biotech clinching regulatory approval for a key diagnostic test. In a statement Tuesday, T2 Biosystems TTOO ...
T2 Biosystems (NASDAQ: TTOO) has long had a basic problem. Their systems and tests work just fine but there’s been no compelling or grand reason for anyone to buy one. Therefore the overheads of ...
T2 Biosystems Inc. received a third FDA breakthrough device designation with its direct-from-blood molecular diagnostic test for Candida auris. The test joins its T2resistance panel and T2Lyme panel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results